Renal Function after Radioligand Treatment with 177Lu-PSMA-617

被引：0
作者：
Ngoc, Christina Nguyen [1 ]
Happel, Christian [1 ]
Davis, Karen [1 ]
Groener, Daniel [1 ]
Mader, Nicolai [1 ]
Mandel, Philipp [2 ]
Tselis, Nikolaos [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构：
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Radiooncol, Frankfurt, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1279
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    [J]. ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [22] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    [J]. CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
  • [23] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [24] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    [J]. CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [25] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [26] Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
    Tuchayi, Abuzar Moradi
    Yadav, Surekha
    Jiang, Fei
    Kim, Sarasa T.
    Saelee, Rachelle K.
    Morley, Amanda
    Juarez, Roxanna
    Lawhn-Heath, Courtney
    Wang, Yingbing
    de Kouchkovsky, Ivan
    Hope, Thomas A.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (05) : 735 - 739
  • [27] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    [J]. JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [28] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [29] Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617
    Wei, Xiao
    Schlenkhoff, Carl
    Sopora, Claudia
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. CLINICAL NUCLEAR MEDICINE, 2016, 41 (11) : 894 - +
  • [30] Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Prasad, Vikas
    Heinzel, Aelxander
    Ruf, Juri
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang
    Krause, Bernd J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345